NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Neumora Class Action Lawsuit

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading information in its IPO documents, which has resulted in significant stock price decline since the IPO [1][4]. Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases [2]. IPO Details - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.7 million shares at a price of $17.00 per share [2]. Allegations in the Lawsuit - The lawsuit claims that the IPO offering documents were materially false and misleading, failing to disclose critical information regarding the Phase Two and Phase Three clinical trials of Neumora's flagship therapeutic candidate, Navacaprant [3]. - Specific allegations include the amendment of trial inclusion criteria to justify the Phase Three program and the lack of adequate data in the Phase Two trials to predict outcomes accurately [3]. Stock Performance - Following the IPO, Neumora's stock price has plummeted from $17.00 per share to $1.91 per share as of February 5, 2025, representing an 88.7% decline [4].